香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CARsgen Therapeutics Holdings Limited 科濟藥業控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2171） 自願公告 2025年ESMO年會上呈列的 舒瑞基奧侖賽注射液研究成果 本公告由科濟藥業控股有限公司（「本公司」，連同其附屬公司及併表聯屬實體統 稱「本集團」或「科濟藥業」）自願作出，以告知本公司股東及潛在投資者本集團最 新業務更新。 本公司董事會（「董事會」）宣佈，舒瑞基奧侖賽注射液（產品編號：CT041，一種靶 向Claudin18.2的自體CAR-T細胞治療候選產品）在中國開展的針對胰腺癌(PC)輔 助治療的中國Ib期臨床試驗（CT041-ST-05，NCT05911217）研究結果已於2025年 10月19日（星期日）歐洲中部夏令時間(CEST)12:00-12:45在2025年歐洲腫瘤內科 學會(ESMO)年會上進行壁報 ...

致：香港交易及結算所有限公司 公司名稱: 科濟藥業控股有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 200,000,000,000 | USD | | 0.00000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 200,000,000,000 | USD | | 0.00000025 | USD | | 50,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 本 ...

Major Events - Huiying Holdings (00821) plans to establish a joint venture to provide training, professional consulting services, and high-end conference business in the RWA category [1] - MIRXES-B (02629) intends to set up a joint venture for research, development, and commercialization of early cancer detection and other nucleic acid-based tests in Malaysia [1] - Kintor Pharmaceutical-B (02171) will present updates on the research results of CT0596 at the 2025 ASH annual meeting [1] - Energy & Energy Global (01142) has had its mining license revoked by a Russian subsidiary and plans to appeal further [1] Operating Performance - C&D International Group (01908) reported a cumulative contract sales amount of approximately 71.03 billion yuan for the first nine months, representing a year-on-year increase of about 7.5% [1] - Sa Sa International (00178) recorded a total revenue of 1.031 billion HKD for the second quarter, an annual increase of 8.4% [1] Buybacks/Reductions - Hang Seng Bank (00011) repurchased 200,000 shares for 23.9836 million HKD on October 6 [1] - Tencent Holdings (00700) repurchased 815,000 shares for 550.3 million HKD on October 6 [1] - Mengniu Dairy (02319) repurchased 1 million shares for 14.4099 million HKD on October 6 [1] - HSBC Holdings (00005) repurchased 1.49 million shares for 163 million HKD on October 3 [1]

Core Viewpoint - Hong Kong's biopharmaceutical stocks experienced a significant afternoon rally, indicating positive market sentiment in the sector [1] Company Performance - Yongtai Bio-B surged over 12% [1] - Kexing Pharmaceutical-B increased nearly 10% [1] - Tiansheng Pharmaceutical-B rose over 5% [1] - WuXi AppTec-B and Weisheng Pharmaceutical-B both gained over 3% [1]

Core Viewpoint - Hong Kong's biopharmaceutical stocks experienced a significant afternoon rally, indicating positive market sentiment in the sector [2] Group 1: Stock Performance - Yongtai Bio-B surged over 12% [2] - Keji Pharmaceutical-B increased nearly 10% [2] - Tiansheng Pharmaceutical-B rose over 5% [2] - WuXi AppTec-B and Weisheng Pharmaceutical-B both gained over 3% [2]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (科济药业-B) has seen a significant increase in stock price, attributed to the upcoming presentation of clinical data for CT0596 at the 67th American Society of Hematology (ASH) annual meeting and the recent approval of its CAR-T drug for inclusion in insurance directories [1]. Group 1: Stock Performance - Kintor Pharmaceutical's stock price rose over 7% during trading, with a current increase of 5.70%, reaching HKD 19.85 [1]. - The trading volume amounted to HKD 13.3487 million [1]. Group 2: Clinical Data Presentation - The company announced that it will present clinical data for its drug CT0596 at the ASH annual meeting [1]. Group 3: Regulatory Developments - On September 20, the National Healthcare Security Administration announced the completion of expert review work for the first version of the commercial insurance innovative drug directory [1]. - Kintor's CAR-T drug, Sai Ke Ze, along with four other CAR-T drugs, successfully passed the expert review, indicating a potential inclusion in this year's basic medical insurance directory and commercial insurance innovative drug directory [1].

Group 1 - Kintor Pharmaceutical (科济药业-B) shares rose over 7%, currently up 6.39% at HKD 19.98, with a trading volume of HKD 10.51 million [1] - The company announced it will present clinical data for CT0596 at the 67th American Society of Hematology (ASH) annual meeting [1] - On September 20, the National Healthcare Security Administration announced the completion of expert review for the first version of the commercial insurance innovative drug catalog, with Kintor's CAR-T drug, Sai Ke Ze, among five CAR-T drugs that passed the review, potentially entering this year's basic medical insurance and commercial insurance innovative drug catalog [1]

Group 1 - The core point of the article is that Kintor Pharmaceutical (科济药业-B) has seen a stock price increase of over 7%, currently trading at 19.98 HKD with a transaction volume of 10.51 million HKD [1] - Kintor Pharmaceutical announced that it will present clinical data for CT0596 at the 67th American Society of Hematology (ASH) annual meeting [1] - On September 20, the National Healthcare Security Administration announced the completion of expert review for the first version of the commercial insurance innovative drug catalog, with Kintor's CAR-T drug, Sai Ke Ze, among five CAR-T drugs that passed the review, potentially entering the basic medical insurance catalog and commercial insurance innovative drug catalog this year [1]

Core Insights - Company Kintor Pharmaceutical (科济药业-B) announced that it will present clinical data for CT0596, a BCMA-targeted allogeneic CAR-T cell candidate, at the 67th American Society of Hematology Annual Meeting [1] - CT0596 is developed on the company's proprietary THANK-u Plus platform and is currently undergoing investigator-initiated clinical trials for relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL) [1] - The candidate has shown promising safety and efficacy signals, with CAR-T cell expansion observed across all predefined dose groups [1] - The company plans to explore CT0596 in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells [1] - An IND application for CT0596 is expected to be submitted in the second half of 2025 [1]

Core Viewpoint - Company Kintor Pharmaceutical (科济药业-B) is set to present clinical data for its CAR-T cell therapy candidate CT0596 at the 67th American Society of Hematology Annual Meeting, with further details to be released on November 3, 2025 [1] Group 1: Product Information - CT0596 is a universal CAR-T cell therapy targeting BCMA, developed on the company's proprietary THANK-u Plus™ platform [1] - The therapy is currently undergoing investigator-initiated clinical trials for relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL) [1] - Initial results indicate promising safety and efficacy signals, with CAR-T cell expansion observed across all predefined dose groups [1] Group 2: Future Plans - In addition to R/R MM, the company plans to explore CT0596 in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells [1] - The company anticipates submitting an IND application for CT0596 in the second half of 2025 [1]